GT BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.12 USD | -4.59% |
|
-6.17% | -59.22% |
| 26/03 | GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 01/02 | GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall | MT |
GT Biopharma, Inc. specializes in the research and development of therapeutic products used primarily for the treatment of cancer and disorders of the central nervous system.
The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).
Sector
Pharmaceuticals
Calendar
25/06/2024
- Annual General Meeting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.27
USD
Average target price
150
USD
Spread / Average Target
+4,487.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -59.22% | 45.15L | |
| +32.09% | 69TCr | |
| +29.39% | 59TCr | |
| -1.34% | 37TCr | |
| +20.34% | 33TCr | |
| +7.39% | 29TCr | |
| +14.25% | 24TCr | |
| -3.03% | 21TCr | |
| +10.02% | 21TCr | |
| +8.49% | 17TCr |
- Stock Market
- Equities
- GTBP Stock
- Funds and ETFs GT Biopharma, Inc.
